{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:42:03Z","timestamp":1790379723270,"version":"4.1.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.1001\/jamaoncol.2019.2792","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T15:31:24Z","timestamp":1567697484000},"page":"1582","source":"Crossref","is-referenced-by-count":97,"title":["Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"5","author":[{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kaubisch","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Niedzwiecki","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Posey","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Benjamin R.","family":"Tan","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Goel","sequence":"additional","affiliation":[{"name":"Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Lammers","sequence":"additional","affiliation":[{"name":"Meharry Medical College, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Tam","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Rajdev","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Dika","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Zemla","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan I.","family":"Potaracke","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Balletti","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"El-Khoueiry","sequence":"additional","affiliation":[{"name":"Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Suga","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vallejo Medical Center, Vallejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York\u2013Presbyterian Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute, Morgantown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Bertagnolli","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Weill Cornell Medical College, Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi190060r1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"coi190060r2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"20","key":"coi190060r3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/jnci\/dji315","article-title":"A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.","volume":"97","author":"Yeo","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"coi190060r4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/annonc\/mdl017","article-title":"Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.","volume":"17","author":"Richly","year":"2006","journal-title":"Ann Oncol"},{"issue":"19","key":"coi190060r5","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"issue":"7-8","key":"coi190060r6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials.","volume":"27","author":"Zelen","year":"1974","journal-title":"J Chronic Dis"},{"issue":"11","key":"coi190060r7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi190060r8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"coi190060r9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials.","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"issue":"3","key":"coi190060r10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"issue":"2","key":"coi190060r11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"282","key":"coi190060r12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"coi190060r13","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"2","key":"coi190060r14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2344317","article-title":"Asymptotically efficient rank invariant test procedures.","volume":"135","author":"Peto","year":"1972","journal-title":"J R Stat Soc [Ser A]"},{"issue":"2","key":"coi190060r16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"26","key":"coi190060r17","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi190060r18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Treatment of hepatocellular carcinoma with adriamycin: preliminary communication.","volume":"36","author":"Olweny","year":"1975","journal-title":"Cancer"},{"issue":"17","key":"coi190060r19","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone.","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi190060r20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance.","volume":"46","author":"McCubrey","year":"2006","journal-title":"Adv Enzyme Regul"},{"issue":"6","key":"coi190060r21","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1158\/0008-5472.CAN-06-3648","article-title":"Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1.","volume":"67","author":"Alavi","year":"2007","journal-title":"Cancer Res"},{"issue":"15","key":"coi190060r22","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1073\/pnas.140210697","article-title":"Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.","volume":"97","author":"Song","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"coi190060r23","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1038\/s41598-018-23630-w","article-title":"The anti-cancer multikinase inhibitor sorafenib impairs cardiac contractility by reducing phospholamban phosphorylation and sarcoplasmic calcium transients.","volume":"8","author":"Schneider","year":"2018","journal-title":"Sci Rep"},{"issue":"suppl 8","key":"coi190060r24","article-title":"Tumor necrosis as a correlate for response in subgroup of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib","volume":"19","author":"Abou-Alfa","year":"2008","journal-title":"Ann Oncol"},{"issue":"15","key":"coi190060r25","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","article-title":"Future of hepatocellular carcinoma incidence in the United States forecast through 2030.","volume":"34","author":"Petrick","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi190060r15","volume-title":"Encyclopedia of Biostatistics","author":"Harrington","year":"2005"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2749258\/jamaoncology_aboualfa_2019_oi_190060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:43:56Z","timestamp":1721695436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2749258"}},"subtitle":["Phase 3 CALGB 80802 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.2792","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}